Skip to content
Wednesday 12 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,837.48
-0.06%
DAX
26,469.52
+0.30%
CAC 40
8,696.39
-0.21%
STOXX 50
6,556.96
+0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Friday 27 November 2020 4:22 pm

Suspected North Korean hackers ‘target’ Covid-19 vaccine maker Astrazeneca

By: James Warrington

Add as a preferred source on Google
Prime Minister Scott Morrison Announces Deal With AstraZeneca To Supply Potential COVID-19 Vaccine

Suspected North Korean hackers are said to have made multiple attempts to hack into the computer systems of British Covid-19 vaccine maker Astrazeneca.

Hackers posed as recruiters on Linkedin and Whatsapp and approached Astrazeneca staff with fake job offers, Reuters reported, citing sources.

They then sent documents purporting to be job descriptions that were teeming with malicious code designed to break into the victim’s computers.

The attacks are said to have targeted a range of employees at the pharma giant, including those working on its Covid-19 vaccine, but are not thought to have been successful.

Astrazeneca has been contacted for comment.

According to the report, the techniques used in the cyber attacks were consistent with an ongoing hacking campaign that US authorities and cyber experts have attributed to North Korea.

The campaign previously focused on defence companies and media organisations, but is said to have shifted its attention to coronavirus-related targets in recent weeks.

The number of cyber attacks has jumped this year as unscrupulous hackers attempt to capitalise on the pandemic.

The National Cyber Security Centre blocked more than 700 major attacks in the year to the end of August, roughly a quarter of which were related to the virus.

But authorities have warned that hostile states are also attempting to access research and information about Covid-19 vaccines as scientists scramble to roll out a cure for the disease.

The government today formally asked UK medicine regulators to authorise Astrazeneca’s Covid-19 vaccine for emergency supply.

The vaccine, developed with Oxford University, has showed an average efficacy of 70 per cent, though questions have since been raised over the accuracy of the figure.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Tech

Related Topics

  • AstraZeneca

Trending Articles

  • Five-star Mayfair hotel hit with HMRC winding-up petition

  • Nottingham Forest owner Marinakis sues Crystal Palace for defamation

  • Back to basics: Sainsbury’s gradual retreat from the British high street

  • Hargreaves Lansdown orders staff back to office

  • As it happened: Intel, Arm shares slide; Oil climbs higher

More from Morning Wire

  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

    Markets
    Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.
  • Silence Therapeutics Reports Second Quarter 2026 Financial and Business Results

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook